$-0.47 EPS Expected for Cellular Biomedicine Group, Inc. (CBMG) on May, 14

April 17, 2018 - By Mark Mitchell

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Corporate Logo
Big Money Sentiment increased to 0.71 in 2017 Q4. It has change of 0.46, from 2017Q3’s 0.25. The ratio increased due to Cellular Biomedicine Group, Inc. positioning: 4 sold and 3 reduced. 1 funds acquired stakes and 4 increased stakes. Investors holded 562,538 in 2017Q3 but now own 472,598 shares or 15.99% less.
Blackrock stated it has 91,332 shs. Morgan Stanley holds 0% or 1,300 shs in its capital. Tower Research Lc (Trc), New York-based fund reported 453 shs. Meeder Asset Mgmt Inc invested in 549 shs. Northern Corporation owns 30,904 shs. Millennium Management accumulated 102,516 shs. Barclays Public Ltd Company stated it has 0% of its capital in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Dimensional Fund Advsr L P has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Moreover, Vanguard Gru has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Geode Cap Ltd Com invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Bnp Paribas Arbitrage Sa has invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Bridgeway Management reported 69,100 shs. Deutsche State Bank Ag stated it has 123 shs. California Pub Employees Retirement has invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG).

Cellular Biomedicine Group, Inc. had 1 sale and 0 insider purchases since April 10, 2018. This’s net activity of $450,832.

On May, 14. Investors wait Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) to reveal its quarterly earnings, according to RTT. Analysts predict 9.30 % diference or $-0.47 from the $-0.43 EPS from 2017. Wall Street predicts -2.08 % EPS growth as of May, 14. The stock decreased 0.48% or $0.1 during the last trading session, reaching $20.85.Currently Cellular Biomedicine Group, Inc. is uptrending after 64.04% change in last April 17, 2017. CBMG has also 2,938 shares volume. CBMG outperformed the S&P500 by 52.49%.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Ratings Coverage

Total analysts of 2 have positions in Cellular Biomedicine Group (NASDAQ:CBMG) as follows: 1 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 50%. Since February 1, 2018 according to StockzIntelligence Inc Cellular Biomedicine Group has 2 analyst reports. On Thursday, March 8 FBR Capital initiated the shares of CBMG in report with “Buy” rating. In Thursday, February 1 report Maxim Group downgraded the stock to “Hold” rating.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China.The firm is worth $354.27 million. It focuses on developing and marketing cell therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases.Currently it has negative earnings. The firm develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: